• FAQS
  • ABOUT
  • LOG IN
  • SIGN UP

CYNA Overview

Upcoming Projects (CYNA) Image
  • Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (CYNA) Image
  • Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CYNA) Image
  • Cynapsus plans to submit NDA for APL-130277 to the FDA in the first half of 2017
    Tickers: SUNOVION PHARMACEUTICALS, CYNA
    Occurred on: Mar 30, 2018
  • Cynapsus plans to initiate a pivotal clinical program evaluating the safety and efficacy of APL-130277 in PD patients in the fourth quarter of 2016
    Ticker: CYNA
    Occurred on: Aug 29, 2016
  • Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease
    Ticker: CYNA
    Occurred on: Aug 29, 2016
  • Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
    Ticker: CYNA
    Occurred on: Jul 18, 2016
  • Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
    Ticker: CYNA
    Occurred on: Jul 18, 2016
Strategic Initiatives (CYNA) Image
  • Sunovion Pharmaceuticals Acquires Cynapsus Therapeutics for US$40.50 per share in cash
    Tickers: CYNA, Sunovion Pharmaceuticals
    Announcement Date: Aug 31, 2016
  • Cynapsus Therapeutics and MonoSol Rx Announce Global IP Licensing Agreement
    Ticker: CYNA
    Announcement Date: Apr 04, 2016
About Us
  • About
  • Pricing
  • Compliance
  • Terms of Use
  • Privacy Policy
Media Center
  • Jobs
Connect with Us
  • facebook Facebook
  • facebook Twitter
  • facebook LinkedIn
  • facebook Email Us
© 2025 Slingshot Insights. All rights reserved.